Betting scandals leave pro sports just one way to save the $165 billion gaming market
As indictments mount, fans and stock investors are losing trust that only an integrity commissioner can restore. Source link...
MARKET
U.S. stocks have been surprisingly resilient as the Iran conflict threatens global economic disruption. Thank industry analysts?
It probably helps that Wall Street analysts have continued to raise their earnings forecasts, according to Ed Yardeni, founder of Yardeni Research. Source link...
‘I didn’t ask a man to rear-end my car’: Social Security is replacing my disability benefits. Will the fund run out of money?
“I didn’t ask a man to rear-end my car at a red light.” Source link...
New Social Security whistleblower alleges DOGE worker improperly accessed data and planned to share it
According to a report, a former DOGE software engineer allegedly told co-workers that he had two databases of U.S. citizens’ information. Source link...
Stagflation? $150 oil? That doesn’t mean everyone’s 401(k) is losing money.
The problem with crises like this is that stocks and bonds can both fail. Source link...
The Iran conflict could feed a defense boom. Why a rearming world needs more dollars.
There are practical reasons for the dollar’s strength in the Iran conflict: there’s a need for many of our top exports. Source link...
Allegations of insider trading emerge over prediction-market bets tied to Iran conflict
This weekend was a big one for prediction markets like Polymarket and Kalshi, but allegations of insider trading and a controversy surrounding the handling of one particularly sensitive market appear to have set off a firestorm of criticism. Source link...
10-year Treasury yield hits a three-month low — and it may have to do with AI, strategist says
The bond market has caught a bid over much of the past month, with buyers stepping into a crucial part of the $30 trillion Treasury market partly because of anxiety over artificial intelligence’s potential to wipe out many U.S. jobs,...
Novo Nordisk’s stock slips to 4-year low after its next-gen weight-loss drug lost to Lilly’s in Phase 3 trial
Novo Nordisk shares were under pressure on Monday as the struggling Danish pharmaceutical said a head-to-head study found a drug in development didn’t cut as much weight as an Eli Lilly product. Source link...
This once-hot cancer-detection company’s stock got cut in half after a failed trial
Grail’s stock was the Nasdaq’s biggest loser Friday, after a key trial of its Galleri early-detection cancer test failed to meet its primary endpoint. Source link...
Powered By 